巴克莱分析师Emily Field周一在给客户的报告中表示：“虽然目前无疑是一个痛苦的时期，但我们认为这是短期的痛苦，长期的业绩前景仍然完好无损。”她认为，在诺和诺德旗下的实验性药物CagriSema预计将于12月公布试验结果之前，第三季度的业绩是“最后一点坏消息”。The longest upward trend in European medical care stocks since March 2010 is about to end, due to market concerns about the third-quarter performance to be announced by Novo-Nordisk, as well as the experimental drug updates from AstraZeneca and Roche.
According to the ZhuTong Finance and Economics APP, the longest upward trend in European medical care stocks since March 2010 is about to end, due to market concerns about the third-quarter performance to be announced by Novo-Nordisk (NVO.US), as well as the experimental drug updates from AstraZeneca (AZN.US) and Roche (RHHBY.US). Data shows that the STOXX 600 healthcare index has fallen 6.1% so far in September, ending ten consecutive months of gains, with Novo-Nordisk, AstraZeneca, and Roche accounting for about 90% of the index's decline this month.
JPMorgan analyst stated last week that the third-quarter performance to be announced by Novo-Nordisk in November may show that sales of its popular weight-loss drug, Wegovy, are below expectations. The stock price dropped by 16% in September and is expected to record the largest monthly decline since August 2016.
Barclays analyst Emily Field stated in a report to clients on Monday: "Although it is undoubtedly a painful time now, we believe this is short-term pain and the long-term performance outlook remains intact." She believes that the performance in the third quarter is the "last bit of bad news" before the experimental drug CagriSema under Novo-Nordisk is expected to announce trial results in December.
AstraZeneca's stock price is also under pressure, with the stock listed in London falling by 12% so far this month, marking the largest monthly drop since February 2009. At the same time, the experimental drug co-developed with its partner Daiichi Sankyo has generated mixed results, and analysts are concerned about whether the drug will receive regulatory approval.
Roche's stock price declining this month is related to concerns about the side effects of its highly anticipated experimental weight-loss drug, raising doubts in the market about the competitiveness of this new drug from Roche.
On a broader level, investors have been shifting from more defensive sectors to higher-risk sectors, which has to some extent led to the poor performance of European medical care stocks this month. However, novo-nordisk a/s investment analyst Rob Strachan stated: "The short-term price decline means that the valuation of European medical care stocks is more attractive. For long-term investors, the absolute valuation is already quite appealing."
